Both Boomerang Catalyst System devices, along with the innovative supporting resources in Cardiva's Pathway Program, uniquely provide clinicians with the control to achieve rapid hemostasis in the short term with the confidence of safety in the long term, enabling clinicians to go beyond closure to deliver the greatest benefit to patients, nurses, and physicians in and out of the cath lab. "Easy to use, the Boomerang Catalyst System is a significant advancement in the cath lab in terms of enabling rapid hemostasis with early ambulation for nearly all patients without associated complications. The successful adoption of our product demonstrates that the Catalyst System delivers where other approaches fail, yielding unprecedented clinical safety and economic outcomes. With the market approval of the Boomerang Catalyst II System, we are excited about the upcoming launch of this new product, and expect to expand the breadth and depth of benefits demonstrated with the Boomerang Catalyst System," said Augustine Y. Lien, founder, Chairman and Chief Executive Officer of Cardiva Medical.
About the family of Boomerang Catalyst System devices
At the end of the percutaneous procedure, the thin Boomerang Catalyst
System is inserted into the artery through the existing arterial sheath
used during the catheterization procedure. Once inside the artery, the
|SOURCE Cardiva Medical, Inc.|
Copyright©2007 PR Newswire.
All rights reserved